Professor, Radiology, University of Iowa College of Medicine
Radiology
Dr. Malik E. Juweid, MD
|
|
Give Review
Malik Juweid is an expert in the field of Radiology. Malik Juweid is also a published MD. He has 90 paper published. The most recent paper is: Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Publications
- Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Ea...
- Current and future aspects of nuclear molecular therapies: A model of theranostics.
- Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
- FDG-PET/CT in lymphoma.
- Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immun...
- Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background.
- Nasopharyngeal squamous cell carcinoma metastatic to psoas muscle.
- PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity.
- Imaging in early-stage Hodgkin's lymphoma.
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Grou...
- Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi para...
- Modeling combined radiopharmaceutical therapy: a linear optimization framework.
- Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.
- First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.
- Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
- 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
- The role of FDG-PET scans in patients with lymphoma.
- Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
- Positron-emission tomography and assessment of cancer therapy.
- Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma.
- Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
- Role of positron emission tomography in lymphoma.
- Scintigraphic detection of benign struma ovarii in a hyperthyroid patient.
- Corn oil emulsion: a simple cholecystagogue for diagnosis of chronic acalculous cholecystitis.
- Radioimmunotherapy with 131I-rituximab: what we know and what we don't know.
- Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
- Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation.
- Renal cyst uptake following I-131 treatment for thyroid cancer.
- Molecular imaging of proliferation in malignant lymphoma.
- Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.
- Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies.
- FDG-PET lymphoma demonstration project invitational workshop.
- Technology evaluation: epratuzumab, Immunomedics/Amgen.
- 99mTc-depreotide tumour uptake in patients with non-Hodgkin''s lymphoma.
- Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphoma.
- Visualization of infected cardiac pacemaker leads by SPECT In-111 leukocyte imaging.
- FDG positron emission tomographic imaging of pseudo-pseudo tumor.
- Unusual bilateral symmetrical osteolytic metastases visualized by bone scintigraphy.
- A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy.
- Follicular non-Hodgkin''s lymphoma.
- Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
- Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I an...
- Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
- Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
- Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
- Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
- Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats.
- Comparison of 99Tcm-labelled monoclonal anti-granulocyte antibody and 111In-labelled IgG for the detection of focal sites of infection in rats.
- Accumulation of immunoglobulin G at focal sites of inflammation.
- Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.
- Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
- Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
- Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2.
- A simple method for affinity purification of radiolabeled monoclonal antibodies.
- Hepatobiliary scintigraphy: morphine-augmented versus delayed imaging in patients with suspected acute cholecystitis.
- Unilateral medullary sponge kidney detected on bone scan.
- Distribution of deoxyglucose and technetium-99m-glucarate in the acutely ischemic myocardium.
- Cholescintigraphy in the diagnosis of acute cholecystitis: morphine augmentation is superior to delayed imaging.
- Nephrotic syndrome as an unusual paraneoplastic syndrome of Hodgkin's disease demonstrated on gallium-67 scan.
- Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
- Can occult metastases be treated by radioimmunotherapy?
- Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery?
- Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
- The role of nuclear imaging in ischemic heart disease.
- Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
- Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antib...
- Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
- 99Tcm-LL1: a potential new bone marrow imaging agent.
- Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
- Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
- Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
- Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
- Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies.
- Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
- Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
- Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.
- Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies.
- Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
- Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
- Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with mo...
- Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing.
- Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
- Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
- Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed,...
- Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
- Revised response criteria for malignant lymphoma.
- Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin''s lymphoma.
- Peripheral T-cell lymphomas: variably or routinely fluorodeoxyglucose-avid?
- 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma.
Doctors Specialties
- Nuclear Medicine
- Radiology
Accepted Insurances
Education
-
University of Pennsylvania Health System -
University of Heidelberg Faculty of Clinical Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Wyatt L. Hadley, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravi Sood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey Meier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myka C. Veigel, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lonnie D. Vaughn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vitaliy D. Gavrikov, MD |
|
|
Dr. Yusuf Menda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Chaitra Channappa, MB BS
This Doctor is OpenDoctor Recommended.
|